Get the Stockscreener App
0.47
20.34%
-0.12
Intensity Therapeutics Inc stock is traded at $0.47, with a volume of 6.69M.
It is down -20.34% in the last 24 hours and down -8.20% over the past month.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
See More
Previous Close:
$0.59
Open:
$0.5995
24h Volume:
6.69M
Relative Volume:
0.23
Market Cap:
$28.23M
Revenue:
-
Net Income/Loss:
$-16.26M
P/E Ratio:
-0.3978
EPS:
-1.1814
Net Cash Flow:
$-13.50M
1W Performance:
-7.84%
1M Performance:
-8.20%
6M Performance:
+46.87%
1Y Performance:
-77.24%
1-Day Range:
$0.4201
$0.60
1-Week Range:
$0.4201
$0.60
52-Week Range:
$0.1853
$3.1663
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
0.47 | 35.44M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Intensity Therapeutics Inc Stock (INTS) Latest News
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium - PR Newswire
What drives Intensity Therapeutics Inc stock priceTechnology Stock Trends & Explosive Profit Potential - earlytimes.in
You might want to take a look at Intensity Therapeutics Inc (INTS) now - setenews.com
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement - marketscreener.com
INTS Stock Price and Chart — NASDAQ:INTS - TradingView
Update Report: How Intensity Therapeutics Inc stock benefits from global expansionPortfolio Gains Summary & AI Based Trade Execution Alerts - BỘ NỘI VỤ
Intensity Therapeutics gets 180-day extension to meet Nasdaq price rule - Investing.com Nigeria
Intensity Therapeutics receives 180-day Nasdaq extension to regain compliance - MSN
Intensity Therapeutics stock rises after securing Nasdaq listing extension By Investing.com - Investing.com Nigeria
Intensity Therapeutics stock rises after securing Nasdaq listing extension - Investing.com
Intensity Therapeutics Gets Extension to Regain Nasdaq Minimum Price Requirement - marketscreener.com
Intensity Therapeutics Granted Nasdaq Compliance Extension - TipRanks
Intensity Therapeutics granted 180-day extension - marketscreener.com
Intensity Therapeutics gets 180-day extension to meet Nasdaq price rule By Investing.com - Investing.com South Africa
Intensity Therapeutics jumps after Nasdaq grants compliance extension - TradingView — Track All Markets
Intensity Therapeutics granted Nasdaq compliance extension - MSN
Intensity Therapeutics, Inc. (INTS) 18.98% in Intraday Trading: Surge Ahead of Conference Presentations - Stocks Telegraph
Intensity Therapeutics expands at-the-market offering - MSN
Intensity Therapeutics files for offering of up to $30 million common stockSEC filing - marketscreener.com
Intensity Therapeutics expands at-the-market offering program to $30 million - Investing.com Australia
Intensity Therapeutics announces two presentations at the upcoming 2025 San Antonio Breast Cancer Symposium - marketscreener.com
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium - Barchart.com
Intensity Therapeutics expands at-the-market offering program to $30 million By Investing.com - Investing.com South Africa
Intensity Therapeutics Expands At-The-Market Offering - TipRanks
Intensity Therapeutics Expands ATM Offering to $30 Million - TradingView — Track All Markets
Chipmakers Recap: Why FARO Technologies Inc. stock could see breakout soonWall Street Watch & Momentum Based Trading Signals - BỘ NỘI VỤ
How Intensity Therapeutics Inc. stock benefits from global expansionEarnings Recap Report & Verified Chart Pattern Signals - Newser
Delving into the physics of cancer, with Lew Bender - pharmaphorum
Intensity Therapeutics (INTS) Stock Analysis Report | Financials & Insights - Benzinga
The time has not yet come to remove your chips from the table: Intensity Therapeutics Inc (INTS) - setenews.com
Intensity Therapeutics shares plunge 30% after $4 million discounted stock offering - MSN
What analysts say about Intensity Therapeutics Inc stockSwing Trading Watchlist & Free Turn Volatility To Profit - earlytimes.in
Can Intensity Therapeutics Inc. stock resist sector downturnsJuly 2025 Rallies & Weekly High Momentum Picks - moha.gov.vn
Why Intensity Therapeutics Inc. stock appeals to analystsQuarterly Portfolio Review & Free Risk Controlled Daily Trade Plans - moha.gov.vn
Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire) - Aktiellt
Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - Aktiellt
Trading Recap: Will Intensity Therapeutics Inc. stock split attract more investorsJuly 2025 Trade Ideas & Capital Efficiency Focused Strategies - BỘ NỘI VỤ
MSN Money - MSN
Intensity Therapeutics Inc (INTS) looking to reclaim success with recent performance - setenews.com
How Intensity Therapeutics Inc. stock reacts to oil prices2025 Earnings Surprises & Stepwise Trade Signal Implementation - newser.com
Will Intensity Therapeutics Inc. stock benefit from AI adoptionMarket Movement Recap & Free Low Drawdown Momentum Trade Ideas - newser.com
How to integrate Intensity Therapeutics Inc. into portfolio analysis tools2025 Fundamental Recap & Daily Volume Surge Trade Alerts - newser.com
Is Intensity Therapeutics Inc. stock oversold or undervaluedJuly 2025 Decliners & Weekly Market Pulse Updates - newser.com
Will a bounce in Intensity Therapeutics Inc. offer an exitQuarterly Portfolio Summary & Daily Stock Trend Watchlist - newser.com
Will Intensity Therapeutics Inc. stock reach all time highs in 2025July 2025 Sector Moves & Low Risk High Win Rate Stock Picks - newser.com
How supply chain issues affect Intensity Therapeutics Inc. stock2025 Technical Patterns & Technical Confirmation Alerts - newser.com
Will Intensity Therapeutics Inc. rebound enough to break evenJuly 2025 Trade Ideas & AI Powered Market Entry Ideas - newser.com
Stocks of Intensity Therapeutics Inc (INTS) are poised to climb above their peers - setenews.com
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):